/
PEN
$318.57+$2.14 (+0.68%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.4B
39M shares
52-week range
$221.26 – $362.41
69% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Borrow rate
0.76%
Easy to borrow
Price (6 mo)
Change+$42.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $444.9M | $547.4M | $560.4M | $747.6M | $847.1M | $1.06B | $1.19B | $1.40B |
| Cost of revenue | $152.4M | $175.4M | $222.2M | $272.2M | $311.9M | $375.9M | $439.6M | $461.2M |
| Gross profit | $292.5M | $372.0M | $338.2M | $475.4M | $535.2M | $682.6M | $755.0M | $942.4M |
| Gross margin | 65.7% | 68.0% | 60.3% | 63.6% | 63.2% | 64.5% | 63.2% | 67.1% |
| R&D | $36.2M | $51.7M | $90.0M | $104.6M | $79.4M | $84.4M | $94.8M | $89.8M |
| Operating income | −$852.0K | $47.5M | −$38.9M | −$7.5M | $6.1M | $73.6M | $9.3M | $189.2M |
| EBITDA | $36.2M | $55.6M | −$26.1M | $7.8M | $30.0M | $108.6M | $46.0M | $222.6M |
| Net income | $6.6M | $48.5M | −$15.7M | $5.3M | −$2.0M | $91.0M | $14.0M | $177.7M |
| Net margin | 1.5% | 8.9% | -2.8% | 0.7% | -0.2% | 8.6% | 1.2% | 12.7% |
| EPS (diluted) | 0.18 | 1.34 | -0.54 | 0.14 | -0.05 | 2.32 | 0.36 | 4.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.6B | $4.91 | $4.64–$5.01 | 7 |
| 2027 | $1.8B | $6.16 | $5.33–$6.64 | 8 |
| 2028 | $2.0B | $7.27 | $6.78–$8.59 | 4 |
| 2029 | $2.2B | $8.06 | $7.85–$8.21 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Penumbra, Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
www.penumbrainc.com- Employees
- 4,700
- IPO / List date
- Sep 18, 2015
- HQ
- ALAMEDA, CA
Held by traders on TradeandTell
No one on the platform currently holds PEN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 10,038 | $3.3M |
| Renaissance Technologiesas of 2026-03-31 | 2,160 | $709.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PEN yet.
